Drug Trial Radar · NCT00838253
Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients
Last checked: Nov 19, 2026Latest source record: Oct 23, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Jun 2009
Primary completion
Not stated
Sponsor
- Lead sponsor
- Debiopharm International SAIndustry
- Sponsor type
- Industry
- First posted
- Feb 6, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and efficacy of istaroxime in patients hospitalized for Acute Decompensated Heart Failure (ADHF) not requiring inotropic therapy.This will be done by comparing the hemodynamic effect of a 24-hour infusion of three different doses of the drug versus placebo. Efficacy will be measured as a change in Pulmonary Capillary Wedge Pressure from pre-infusion to 6 hours after infusion start. Secondary objectives will include the evaluation of clinical efficacy and safety through assessment of cardiovascular and renal tolerability as well as changes in biological markers such as brain natriuretic peptide (BNP) and troponin I (TNI), and the neurohormones renin and aldosterone and also to assess the pharmacokinetics of istaroxime and its metabolites.
Conditions
- Heart Failure
Interventions
IstaroximeDrug
Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
IstaroximeDrug
Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
IstaroximeDrug
Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
PlaceboDrug
Placebo continuous i.v. infusion for 24 hours
Primary outcomes
What the sponsor says the trial is designed to measure.
- PCWP change from baselineTime frame: 6 hours after infusion start
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.